<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754845</url>
  </required_header>
  <id_info>
    <org_study_id>MA17R</org_study_id>
    <secondary_id>CAN-NCIC-MA17R</secondary_id>
    <secondary_id>CDR0000614819</secondary_id>
    <nct_id>NCT00754845</nct_id>
  </id_info>
  <brief_title>Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy</brief_title>
  <official_title>A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
      letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is
      not yet known whether letrozole is more effective than a placebo in treating in women with
      breast cancer who have already received 5 years of aromatase inhibitor therapy.

      PURPOSE: This randomized phase III trial is studying letrozole to see how well it works
      compared with a placebo in treating women with primary breast cancer who have received 5
      years of aromatase inhibitor therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the disease-free survival of women with primary breast cancer treated with
           letrozole vs placebo after completing approximately 5 years (i.e., 4½ - 6 years) of
           aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane).

      Secondary

        -  To compare the effect of these drugs on overall (all cause specific) mortality of these
           patients.

        -  To compare the incidence of contralateral breast cancer in patients treated with these
           drugs.

        -  To evaluate the long-term clinical and laboratory safety of aromatase inhibitor therapy,
           particularly cardiovascular morbidity and mortality (e.g., significant coronary artery
           disease, including myocardial infarction and angina requiring percutaneous transluminal
           coronary angioplasty or coronary artery bypass graft, fatal and nonfatal strokes, and
           all vascular deaths); incidence of all bone fractures (with particular emphasis on hip
           and wrist fractures as indicators of osteoporosis); changes in bone density; and common
           toxicities.

        -  To compare overall quality of life (QOL) and menopausal-specific QOL of patients treated
           with these drugs.

      OUTLINE: This is a multicenter study. Patients are stratified according to lymph node status
      at diagnosis (negative vs positive vs unknown), prior adjuvant chemotherapy (yes vs no),
      interval between last dose of aromatase inhibitor therapy and study randomization (&lt; 6 months
      vs 6 months to 2 years), and duration of prior tamoxifen citrate use (0 vs &lt; 2 years vs 2 -
      4½ years vs &gt; 4½ years). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral letrozole once daily for up to 5 years in the absence of
           unacceptable toxicity, disease recurrence, or development of a second malignancy.

        -  Arm II: Patients receive oral placebo once daily for up to 5 years in the absence of
           unacceptable toxicity, disease recurrence, or development of a second malignancy.

      Patients undergo bone mineral density measurement by DEXA scan at baseline (if not done
      within 12 months of study entry), at 24 and 48 months during study therapy, and at the
      completion of study therapy. Some patients also complete quality-of-life questionnaires at
      baseline and at 12, 24, 36, 48, and 60 months.

      After completion of study therapy, patients are followed annually.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2004</start_date>
  <completion_date type="Actual">April 19, 2017</completion_date>
  <primary_completion_date type="Actual">December 21, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Unitil the end of study with a median follow up of 75 months</time_frame>
    <description>It is defined as the months from the day of randomization to the earliest date when a recurrence of the primary disease (recurrence in the breast, chest wall and nodal sites or the development of metastatic disease) or a contralateral breast cancer was observed. Subjects who died without recurrence of the primary disease or the development of the contralateral breast cancer were censored at their death date. If a patient has not recurred, developed a contralateral breast cancer, or died, disease-free survival was censored on the date of the last day the patient was known to be alive. Probability of disease free survival at 5 years is estimated and reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Contralateral Breast Cancer</measure>
    <time_frame>10 years</time_frame>
    <description>The annual incidence rate was estimated based on the time to the development of contralateral breast cancer, which was calculated in months from the day of randomization to the diagnosis date of contralateral breast cancer for subjects who had developed the contralateral breast cancer, to the time of death for the patient who died, or to the last day the patient was known alive for subjects without contralateral breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Until the end of study with a median follow-up of 75 months</time_frame>
    <description>For subjects who died, overall survival was calculated in months from the day of randomization to the date of death. Otherwise, survival was censored at the last day the patient was known to be alive. Probability of overall survival at 5 years is estimated and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Role Function- Physical Scale on SF(Short Form)-36 Health Survey</measure>
    <time_frame>8 years</time_frame>
    <description>Difference between post baseline scores and baseline score of role function-physical scale on SF-36 Health Survey (scale range between 0 and 100 with higher score indicating better quality of life).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1918</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Previously diagnosed with primary breast cancer

          -  Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g., letrozole,
             anastrozole, or exemestane), either as initial therapy or after prior tamoxifen
             citrate, including treatment received as part of clinical trial CAN-NCIC-MA17

               -  Completed aromatase inhibitor therapy ≤ 2 years ago

          -  No metastatic or recurrent disease, contralateral breast cancer, or ductal carcinoma
             in situ in either breast, as determined by the following:

               -  Clinical examination of the breast area, axillae, and neck within the past 60
                  days

               -  Mammogram within the past 12 months*

               -  Chest x-ray within the past 60 days

               -  Bone scan, if alkaline phosphatase &gt; 2 times normal and/or there are symptoms of
                  metastatic disease AND confirmatory x-ray, if bone scan results are questionable,
                  within the past 60 days

               -  Abdominal ultrasound, liver scan, or CT scan of the abdomen within the past 60
                  days, if ALT, AST, or alkaline phosphatase &gt; 2 times normal NOTE: *A baseline
                  mammogram is not required for patients who have undergone bilateral complete
                  mastectomy

          -  Hormone-receptor status:

               -  Estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)
                  primary tumor at the time of diagnosis, defined as a tumor receptor content of &gt;
                  10 fmol/mg protein or receptor positive by immunocytochemical assay (for patients
                  not previously enrolled on clinical trial CAN-NCIC-MA17)

               -  ER+ and/or PR+ primary tumor OR hormone receptor status of primary tumor unknown
                  (for patients previously enrolled on clinical trial CAN-NCIC-MA17)

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 5 years

          -  WBC &gt; 3.0 x 10^9/L OR granulocyte count (polymorphs + bands) ≥ 1.5 times 10^9/L

          -  Platelet count &gt; 100 x 10^9/L

          -  AST and/or ALT &lt; 2 times upper limit of normal (ULN)*

          -  Alkaline phosphatase &lt; 2 times ULN*

          -  Able (i.e. sufficiently fluent) and willing to complete quality-of-life questionnaires
             in either English or French (NCIC CTG participating centers)

               -  Inability to complete questionnaires due to illiteracy in English or French, loss
                  of sight, or other equivalent reason allowed

          -  Accessible for treatment and follow-up

          -  No other prior or concurrent malignancy except adequately treated, superficial
             squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other
             cancer treated &gt; 5 years ago that is presumed cured NOTE: *Elevated levels allowed
             provided imaging examinations have ruled out metastatic disease

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene)

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E. Goss, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vitalite Health Network - Dr. Leon Richard</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Health Centre at Southlake</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cancer Center Health Sciences</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre - West Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Regional Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEI Cancer Treatment Centre,Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Sante et de services sociaux de Gatineau</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8P 7H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Hotel-Dieu de Levis</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hotel Dieu du Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5.</citation>
    <PMID>27264120</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>February 23, 2017</results_first_submitted>
  <results_first_submitted_qc>November 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2018</results_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Letrozole</title>
          <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
letrozole: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
placebo: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="959"/>
                <participants group_id="P2" count="959"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="959"/>
                <participants group_id="P2" count="959"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Letrozole</title>
          <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
letrozole: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="959"/>
            <count group_id="B2" value="959"/>
            <count group_id="B3" value="1918"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" lower_limit="43" upper_limit="92.2"/>
                    <measurement group_id="B2" value="64.8" lower_limit="43.4" upper_limit="89.9"/>
                    <measurement group_id="B3" value="65.1" lower_limit="43" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="959"/>
                    <measurement group_id="B2" value="959"/>
                    <measurement group_id="B3" value="1918"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="940"/>
                    <measurement group_id="B2" value="939"/>
                    <measurement group_id="B3" value="1879"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="683"/>
                    <measurement group_id="B2" value="674"/>
                    <measurement group_id="B3" value="1357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>ECOG Performance Status
Grade 0: Fully active, able to carry on all pre-disease performance without restriction
Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
Grade 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="852"/>
                    <measurement group_id="B2" value="856"/>
                    <measurement group_id="B3" value="1708"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>It is defined as the months from the day of randomization to the earliest date when a recurrence of the primary disease (recurrence in the breast, chest wall and nodal sites or the development of metastatic disease) or a contralateral breast cancer was observed. Subjects who died without recurrence of the primary disease or the development of the contralateral breast cancer were censored at their death date. If a patient has not recurred, developed a contralateral breast cancer, or died, disease-free survival was censored on the date of the last day the patient was known to be alive. Probability of disease free survival at 5 years is estimated and reported.</description>
        <time_frame>Unitil the end of study with a median follow up of 75 months</time_frame>
        <population>All women randomized were included in the analysis based on treatment arm they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
letrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>It is defined as the months from the day of randomization to the earliest date when a recurrence of the primary disease (recurrence in the breast, chest wall and nodal sites or the development of metastatic disease) or a contralateral breast cancer was observed. Subjects who died without recurrence of the primary disease or the development of the contralateral breast cancer were censored at their death date. If a patient has not recurred, developed a contralateral breast cancer, or died, disease-free survival was censored on the date of the last day the patient was known to be alive. Probability of disease free survival at 5 years is estimated and reported.</description>
          <population>All women randomized were included in the analysis based on treatment arm they were randomized.</population>
          <units>probability of DFS at 5 years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="959"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.93" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.89" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by the stratification factors at randomization</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Contralateral Breast Cancer</title>
        <description>The annual incidence rate was estimated based on the time to the development of contralateral breast cancer, which was calculated in months from the day of randomization to the diagnosis date of contralateral breast cancer for subjects who had developed the contralateral breast cancer, to the time of death for the patient who died, or to the last day the patient was known alive for subjects without contralateral breast cancer</description>
        <time_frame>10 years</time_frame>
        <population>All women randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
letrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Contralateral Breast Cancer</title>
          <description>The annual incidence rate was estimated based on the time to the development of contralateral breast cancer, which was calculated in months from the day of randomization to the diagnosis date of contralateral breast cancer for subjects who had developed the contralateral breast cancer, to the time of death for the patient who died, or to the last day the patient was known alive for subjects without contralateral breast cancer</description>
          <population>All women randomized</population>
          <units>Number of new case per 1000 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="959"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.0" upper_limit="3.2"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.2" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>For subjects who died, overall survival was calculated in months from the day of randomization to the date of death. Otherwise, survival was censored at the last day the patient was known to be alive. Probability of overall survival at 5 years is estimated and reported.</description>
        <time_frame>Until the end of study with a median follow-up of 75 months</time_frame>
        <population>All women randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
letrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>For subjects who died, overall survival was calculated in months from the day of randomization to the date of death. Otherwise, survival was censored at the last day the patient was known to be alive. Probability of overall survival at 5 years is estimated and reported.</description>
          <population>All women randomized</population>
          <units>probability of OS at 5 years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="959"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.92" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.92" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Role Function- Physical Scale on SF(Short Form)-36 Health Survey</title>
        <description>Difference between post baseline scores and baseline score of role function-physical scale on SF-36 Health Survey (scale range between 0 and 100 with higher score indicating better quality of life).</description>
        <time_frame>8 years</time_frame>
        <population>All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
letrozole: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Role Function- Physical Scale on SF(Short Form)-36 Health Survey</title>
          <description>Difference between post baseline scores and baseline score of role function-physical scale on SF-36 Health Survey (scale range between 0 and 100 with higher score indicating better quality of life).</description>
          <population>All randomized patients.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="959"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.74" spread="1.09"/>
                    <measurement group_id="O2" value="-6.28" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During protocol treatment of 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
letrozole: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
placebo: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage/bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Melena/GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Rectal bleeding/ hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Common Toxicity Crit">Cardiac troponin I (cTnI)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia (PVCs/bigeminy/trigeminy/ ventricular tachycardia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Cardiac left ventricular function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias (SVT/atrial fibrillation/ flutter)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Cardiovascular/ General - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/ failure (clinical)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Hepatic - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second malignacy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="863" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="841" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Common Toxicity Crit">Edema</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title vocab="Common Toxicity Crit">Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/ flushes</sub_title>
                <counts group_id="E1" subjects_affected="360" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="354" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="346" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="355" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="513" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="475" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="240" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="317" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="288" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="269" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="954"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="954"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Biostatistician</name_or_title>
      <organization>Canadian Cancer Trials Group</organization>
      <phone>6135336430</phone>
      <email>dtu@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

